Plasma extravasation mediated by lipopolysaccharide-induction of kinin B1 receptors in rat tissues.
The present study was performed to: (a) evaluate the effects of kinin B1 (Sar[D-Phe8]-des-Arg9-BK; 10 nmol/kg) and B2 (bradykinin (BK); 10 nmol/kg) receptor agonists on plasma extravasation in selected rat tissues; (b) determine the contribution of a lipopolysaccharide (LPS) (100 microg/kg) to the effects triggered by B1 and B2 agonists; and (c) characterize the selectivity of B1 ([Leu8]desArg9-BK; 10 nmol/kg) and B2 (HOE 140; 10 nmol/kg) antagonists as inhibitors of this kinin-induced phenomenon. B1 and B2 agonists were shown to increase plasma extravasation in the duodenum, ileum and also in the urinary bladder of the rat. LPS pretreatment enhanced the plasma extravasation mediated only by the B1 agonist in the duodenum, ileum, trachea, main and segmentar bronchi. These effects were prevented by the B1. but not the B2 antagonist. In normal rats, the B2 antagonist inhibited the effect of B2 agonist in all the tissues analyzed. However, in LPS-treated rats, the B2 antagonist was ineffective in the urinary bladder. These results indicate that kinins induce plasma extravasation in selected rat tissues through activation of B1 and B2 receptors, and that LPS selectively enhances the kinin effect on the B1 receptor in the duodenum, ileum, trachea and main and segmentar bronchi, and may increase B1 receptor expression in these tissues.
Wille
P R
PR
Departamento de Ciencias Fisiologicas, Universidade Federal de Santa Catarina, Florianopolis, Brazil.
Vitor
R
R
Gabilan
N H
NH
Nicolau
M
M
D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D004386:Duodenum / Q000187:drug effects / Q000276:immunology; D007082:Ileum / Q000187:drug effects / Q000276:immunology; D007609:Kallidin / Q000031:analogs & derivatives / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology*; D051381:Rats; D017208:Rats, Wistar; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000819:agonists / Q000276:immunology*; D014132:Trachea / Q000187:drug effects / Q000276:immunology; D001743:Urinary Bladder / Q000187:drug effects / Q000276:immunology
D065168:Bradykinin Receptor Antagonists; D008070:Lipopolysaccharides; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin; C082229:bradykinin, Lys-Leu(8)-desArg(9)-; C072121:bradykinin, Sar-(D-Phe(8))des-Arg(9); D007609:Kallidin; C065679:icatibant; D001920:Bradykinin